Charles River Laboratories International, Inc. (NYSE:CRL) is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 1.80 per share.
Looking ahead, the full year income are expected at $ 7.26 per share on the revenues of $ 2851.89 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2,817.58 million ~ $ 2,857.00 million, where as bottomline are predicted in a range of $ 7.05 ~ $ 7.35 per share
Click Here For More Historical Outlooks Of Charles River Laboratories International, Inc.
Previous Quarter Performance
Charles River Laboratories International, Inc. disclosed income for the second quarter of $ 1.58 per share, from the revenue of $ 682.58 million. The quarterly earnings down 3.07 percent while revenues elevated 3.03 percent compared with the same quarter last year.
Wall street analysts are predicting, CRL to report 2Q20 income of $ 1.26 per share from revenue of $ 641.63 million. The bottom line results beat street analysts by $ 0.32 or 25.40 percent, at the same time, top line results outshined analysts by $ 40.95 million or 6.38 percent.
Stock Performance
Shares of Charles River Laboratories International, Inc. traded low $ -7.26 or -3.17 percent on Wednesday, reaching $ 222.00 with volume of 249.80 thousand shares. Charles River Laboratories International, Inc. has traded high as $ 225.25 and has cracked $ 221.90 on the downward trend
According to the previous trading day, closing price of $ 222.00, representing a 139.86 % increase from the 52 week low of $ 95.58 and a 8.4 % decrease over the 52 week high of $ 250.29.
The company has a market capital of $ 11.03 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Charles River Laboratories International, Inc. will be hosting a conference call at 9:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.criver.com
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers.
